Last updated 2026-07-26
- Raised $30M Undisclosed Round led by Columbus Venture Partners, Dec 2024
- Raised $5M grant, Sep 2022
- Raised $5.7M Undisclosed Round led by Catalyst, Feb 2020
Total raised
$40.7M
Last: Undisclosed Round 2025-01
Stage
Seed
Founded
2016
Headcount
3
HQ
Tel Aviv-Yafo, Israel
Sector
Health Tech & Life Sciences
About
Lutris Pharma is a clinical-stage biopharmaceutical company dedicated to enhancing the effectiveness of anti-cancer therapies and improving the quality of life for patients. The company focuses on reducing cutaneous dose-limiting toxicity associated with EGFR (Epidermal Growth Factor Receptor) inhibitors and radiation therapy, which often leads to reduced treatment compliance. Lutris Pharma develops novel topical therapies to mitigate these side effects. Their lead asset, LUT014, is a topical B-Raf inhibitor.
Funding history · 4 rounds · $40.7M total
2024-12
Undisclosed Round
$30.0M
★ Columbus Venture PartnersPontifaxaMoon FundPeregrine Ventures
2022-09
Grant
$5.0M
2020-02
Undisclosed Round
$5.7M
★ Catalyst★ Pontifax★ Arkin Bio
2016-05
Undisclosed Round
Undisclosed
★ Arkin Bio
Headcount over time
From 4 (2022-01) to 5 (2025-12) · +1 (+25%) · 5 points · source: Finder history + radar grounding
Q&A
- What is Lutris Pharma's primary focus?
- Lutris Pharma is a clinical-stage biopharmaceutical company focused on improving anti-cancer therapies by reducing cutaneous dose-limiting toxicity associated with EGFR inhibitors and radiation therapy.
- What is Lutris Pharma's lead asset?
- Lutris Pharma's lead asset is LUT014, a topical B-Raf inhibitor designed to mitigate skin side effects from anti-cancer treatments.
- When did Lutris Pharma complete enrollment for its Phase 2 trial of LUT014?
- In October 2024, Lutris Pharma completed enrollment in its Phase 2 trial of LUT014 for the treatment of EGFRi-induced acneiform rash in patients with metastatic colorectal cancer.
- What was the most recent funding round for Lutris Pharma?
- In January 2025, Lutris Pharma raised $30,000,000 in a Series B round with participation from.
- When did Lutris Pharma present new data from its completed clinical trial of LUT014 gel?
- In April 2025, Lutris Pharma presented new data from its completed clinical trial of LUT014 gel, demonstrating efficacy in treating acneiform rash associated with anti-EGFR cancer therapies at the AACR Annual Meeting.
- What is the current employee count for Lutris Pharma?
- Lutris Pharma has 1-10 employees.
- When was Lutris Pharma founded?
- Lutris Pharma was founded in 2016.
- Who is the CEO of Lutris Pharma?
- Noa Shelach is the CEO of Lutris Pharma.
Team · 2
Antoni Ribas
Founder · Founder & Chairman
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsMoleculesCells
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B
Highlights
1 Patents
Tags
topical-treatmentcell-therapycancerpharma-companiespharmaceuticalsdermatologycancer-therapy
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | lutris-pharma.com |
|---|---|
| linkedin.com/company/79633164 |
Identifiers & details
| Legal name | Lutris Pharma Ltd. |
|---|---|
| Founded | 2016 |
| Employees (exact) | 3 |
Radar intelligence
Patents
| EPO | 5 |
|---|
Web history (Wayback)
| Domain | lutris-pharma.com |
|---|
Certificate / subdomain footprint
| Subdomains | 1 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 515356236 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2015-12-14 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2024 |
| Active charges / liens | 0 |
| Registry events | 4 — other (1), people (2), shares_capital (1) |
| Registered address | הברזל 27 תל אביב - יפו |
Recent registry events
| Date | Event |
|---|---|
| 2025-08-31 | שינוי בתקנון |
| 2026-04-30 | עדכון דירקטורים-הוספת דירקטור |
| 2026-04-30 | עדכון דירקטורים-הסרת דירקטור |
| 2025-08-28 | הגדלה של הון רשום |